- Home
- Publications
- Publication Search
- Publication Details
Title
Vortioxetine: a New Treatment for Major Depressive Disorder
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 17, Issue 3, Pages 421-431
Publisher
Informa Healthcare
Online
2015-12-18
DOI
10.1517/14656566.2016.1133588
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment of cognitive dysfunction in major depressive disorder—a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine
- (2015) Alan L. Pehrson et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Vortioxetine in Adults With Major Depressive Disorder
- (2015) Atul R. Mahableshwarkar et al. JOURNAL OF CLINICAL PSYCHIATRY
- A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Vortioxetine 10 mg and 20 mg in Adults With Major Depressive Disorder
- (2015) Paula L. Jacobsen et al. JOURNAL OF CLINICAL PSYCHIATRY
- Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data
- (2015) Connie Sanchez et al. PHARMACOLOGY & THERAPEUTICS
- A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD
- (2015) Atul R. Mahableshwarkar et al. PSYCHOPHARMACOLOGY
- A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelat
- (2014) Stuart A. Montgomery et al. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
- Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder
- (2014) Michael E. Thase et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats
- (2014) Ashley Wallace et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults
- (2014) Roger S. McIntyre et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- The US Food and Drug Administration’s Perspective on the New Antidepressant Vortioxetine
- (2014) Jing Zhang et al. JOURNAL OF CLINICAL PSYCHIATRY
- Efficacy and Safety of Vilazodone in Major Depressive Disorder
- (2014) Harry A. Croft et al. JOURNAL OF CLINICAL PSYCHIATRY
- Clinical development success rates for investigational drugs
- (2014) Michael Hay et al. NATURE BIOTECHNOLOGY
- Efficacy and Safety of Prolonged-Release Trazodone in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Flexible-Dose Trial
- (2014) Lin Zhang et al. PHARMACOLOGY
- Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant
- (2013) Grace Chen et al. CLINICAL DRUG INVESTIGATION
- Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: Evidence for direct 5-HT receptor modulation
- (2013) Jesper Bornø Jensen et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder
- (2013) Mohammed Y. Alam et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day
- (2013) Jean-Philippe Boulenger et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice
- (2013) Jean-Philippe Guilloux et al. NEUROPHARMACOLOGY
- Rediscovering Trazodone for the Treatment of Major Depressive Disorder
- (2012) Andrea Fagiolini et al. CNS DRUGS
- Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder
- (2012) David S. Baldwin et al. CURRENT MEDICAL RESEARCH AND OPINION
- A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder
- (2012) Atul R. Mahableshwarkar et al. CURRENT MEDICAL RESEARCH AND OPINION
- P.2.h.002 Effects of the multimodal antidepressant Lu AA21004 on rat synaptic and cellular hippocampal plasticity and memory recognition
- (2012) N. Haddjeri et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters—A rat microdialysis and electrophysiology study
- (2012) Alan L. Pehrson et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder
- (2012) Cornelius Katona et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder
- (2012) Rakesh Jain et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- A Randomized, Double-Blind, Placebo-Controlled 8-Week Trial of the Efficacy and Tolerability of Multiple Doses of Lu AA21004 in Adults With Major Depressive Disorder
- (2012) Neven Henigsberg et al. JOURNAL OF CLINICAL PSYCHIATRY
- A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder
- (2012) Jean-Philippe Boulenger et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Occupancy of the Serotonin Transporter after Administration of Lu AA21004 and its Relation to Plasma Concentration in Healthy Subjects
- (2011) Johan Areberg et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder
- (2011) Enric Alvarez et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- A Randomized, Double-Blind, Placebo-Controlled, 8-Week Study of Vilazodone, a Serotonergic Agent for the Treatment of Major Depressive Disorder
- (2011) Arif Khan et al. JOURNAL OF CLINICAL PSYCHIATRY
- Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
- (2011) Benny Bang-Andersen et al. JOURNAL OF MEDICINAL CHEMISTRY
- National Trends in the Treatment for Depression From 1998 to 2007
- (2010) Steven C. Marcus et al. ARCHIVES OF GENERAL PSYCHIATRY
- Age at onset and latency to treatment (duration of untreated illness) in patients with mood and anxiety disorders: a naturalistic study
- (2010) Alfredo Carlo Altamura et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Evidence for Efficacy and Tolerability of Vilazodone in the Treatment of Major Depressive Disorder
- (2009) Karl Rickels et al. JOURNAL OF CLINICAL PSYCHIATRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started